Charlottesville-based biopharmaceutical company Diffusion Pharmaceuticals Inc. is making waves with its innovative oxygen delivery enhancing therapies. The firm's marquee product candidate, Trans Sodium Crocetinate, has been hailed as a potential game-changer for the treatment of COVID-19, thanks to its ability to greatly improve the diffusion of oxygen to bodily tissues. Founded in 2001, Diffusion Pharmaceuticals is at the forefront of a crucial sector of the healthcare industry that is focused on improving oxygen delivery to improve patient outcomes.